Andrew’s practice focuses on representing public and private life sciences companies in a wide range of commercial transactions – including formations, venture capital financings, initial public offerings, technology licenses, research and development collaborations, and distribution and manufacturing agreements. Andrew also advises companies with respect to Securities and Exchange Commission reporting obligations, corporate governance, and other corporate and securities law matters.
